問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Tri-Service General Hospital

List

851Cases

2018-10-01 - 2020-08-25

Phase II

A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Testicular Safety of Filgotinib in Adult Males with Moderately to Severely Active Ulcerative Colitis

  • Condition/Disease

    Ulcerative Colitis

  • Test Drug

    Filgotinib (GS-6034)

Participate Sites
7Sites

Terminated6Sites

2019-06-01 - 2025-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2017-02-17 - 2020-12-17

Phase III

A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn’s Disease

  • Condition/Disease

    Crohn’s Disease

  • Test Drug

    Filgotinib

Participate Sites
13Sites

Recruiting8Sites

Terminated3Sites

邱正堂
Linkou Chang Gung Medical Foundation

Division of General Internal Medicine

吳登強
Kaohsiung Municipal Gangshan Hospital

未分科

2017-02-17 - 2020-12-17

Phase III

Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease

  • Condition/Disease

    Active Crohn’s Disease

  • Test Drug

    Filgotinib, 100 mg and 200 mg per tablet

Participate Sites
14Sites

Recruiting9Sites

Terminated3Sites

吳登強
Kaohsiung Municipal Gangshan Hospital

未分科

邱正堂
Linkou Chang Gung Medical Foundation

2018-05-25 - 2028-12-31

Phase III

A Multicenter, Double-blind, Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects with Rheumatoid Arthritis

  • Condition/Disease

    Rheumatoid Arthritis

  • Test Drug

    Filgotinib

Participate Sites
10Sites

Recruiting1Sites

Terminated9Sites

方耀凡
Linkou Chang Gung Medical Foundation

張棋楨
Taipei Medical University Hospital

2010-07-01 - 2011-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2005-12-01 - 2008-06-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2012-09-01 - 2016-12-31

Phase III

A Multi-center, Open-Label, Adaptive, Randomized Study of Palifosfamide-tris, a Novel DNA Crosslinker, in Combination with Carboplatin and Etoposide (PaCE) Chemotherapy versus Carboplatin and Etoposide (CE) Alone in Chemotherapy Naïve Patients with Extensive-Stage Small Cell Lung Cancer. The MATISSE Study

  • Condition/Disease

    Small cell lung cancer

  • Test Drug

    Palifosfamide-tris

Participate Sites
7Sites

Terminated7Sites

2014-01-01 - 2020-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2011-05-01 - 2014-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

1 55 56 57 58 59 86
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB